List of Therapeutic Companies in Illinois - 58

Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritional and branded generic medicines. Our 114,000 colleagues serve people in more than 160 countries. Connect with us at www.abbott.com, on Facebook at www.facebook.com/Abbott and www.facebook.com/AbbottCareers, on Instagram @AbbottGlobal, and on X @AbbottNews. We invite you to explore opportunities at Abbott, to see if your talents and career aspirations may fit with our openings. An equal opportunity employer, Abbott welcomes and encourages diversity in our workforce. Terms of Use: https://www.abbott.com/social-media-terms-of-use.htm

AbbVie is a global biopharmaceutical company focused on creating medicines and solutions that put impact first — for patients, communities, and our world. We aim to address complex health issues and enhance people's lives through our core therapeutic areas: immunology, oncology, neuroscience, eye care, aesthetics and other areas of unmet need. Learn more about us at www.abbvie.com and review our community guidelines at https://www.abbvie.com/social-media-community-guidelines.html.

Adze Biotechnology is a biotechnology company that develops a platform of immunotherapies to treat solid tumors and enhance anti-tumor immunity.

AKAVA Therapeutics is developing first-in-class small molecule therapeutics that inhibit protein aggregation, inhibit enzymes and inhibit cancer for a variety of neurodegenerative diseases.

AltaThera Pharmaceuticals is a specialty pharmaceutical company focused on identifying, acquiring, developing and commercializing therapies for the unmet medical needs of critical care patients and those with severe, often rare, disorders for which few effective treatments are available.

Amphix Bio spun out from Northwestern University in Chicago, IL in 2021. The company is developing a new class of supramolecular therapies that instruct cells to initiate regenerative processes and restore function lost from injury, disease, or aging. These therapies contain tens of thousands of biological signals that trigger targeted signaling pathways while forming scaffolds to support tissue growth. Amphix Bio's goal is to use regenerative medicine to increase human healthspans — the length of time that people can live productive, fulfilling lives.

Through our drug development expertise in brain & CNS disorders, we have developed a unique medicinal chemistry platform to discover novel product candidates. The compounds we have discovered work through modulation of NMDA receptors to avoid caustic effects associated with over-activation or full inhibition.

As a global partner to the biopharmaceutical industry, Asahi Kasei Bioprocess helps biologics manufacturers safely and efficiently produce medicines that patients can trust, by dependably supplying innovative yet exceptionally reliable bioprocess consumables, equipment and scientific support services. Our portfolio is anchored by Planova™ virus removal filters. First released in 1989 as the world's first hollow fiber filter developed specifically for removing viruses from biotherapeutic drug products, Planova™ filters ensure viral safety of biopharmaceutical drug products, thanks to their high quality and consistent performance. Leveraging 30 years of experience, we continue to provide our customers with products, services and expertise to achieve assurance that is beyond expectation. As part of our dedication to solving therapeutic product safety, efficiency and purity challenges, we also manufacture a comprehensive suite of downstream equipment. With technology platforms for virus filtration, chromatography, inline buffer formulation and oligonucleotide synthesis, our bioprocessing systems, columns and automation solutions advance GMP manufacturing of critical drug substances around the world. Our portfolio of market-driven equipment and cutting-edge technology touches unit operations across a wide range of therapeutic modalities, including classical small molecule pharmaceuticals, current-generation antibodies, plasma derivatives and next-generation oligonucleotide therapeutics.

Assertio Holdings, Inc., a commercial pharmaceutical company, provides medicines in the areas of neurology, hospital, and pain and inflammation. The company’s pharmaceutical products include INDOCIN, an oral solution and a suppository form for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; moderate to severe ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provides CAMBIA, a non-steroidal anti-inflammatory drug (NSAID) for the treatment of migraine, nausea, photophobia, and phonophobia; Zipsor, an NSAID for relief of mild to moderate acute pain; and SPRIX, an NSAID for the short term management of moderate to moderately severe pain that requires analgesia at the opioid level. The company was formerly known as Assertio Therapeutics, Inc. and changed its name to Assertio Holdings, Inc. in May 2020. Assertio Holdings, Inc. was incorporated in 1995 and is headquartered in Lake Forest, Illinois.

Astellas Pharma US, Inc. is an affiliate of Tokyo-based Astellas Pharma Inc., a top 20 global pharmaceutical research company. Astellas is committed to turning innovative science into medical solutions that bring value and hope to patients and their families. Keeping our focus on addressing unmet medical needs and conducting our business with ethics and integrity enables us to improve the health of people throughout the Americas and around the world. All content developed by Astellas Pharma US, Inc. and intended for U.S. audiences.

Pioneered by accomplished business leaders, guided by world-class biomedical and life science experts, and financed through equity crowdfunding, BIOLIFE4D is driving a movement to transform the treatment of heart disease, the leading cause of death worldwide. Leveraging advances in life sciences and cardiac tissue engineering to build human hearts suitable for implantation, this biotech company is committed to optimizing the process and technology around viable human organ replacement, and making it a safe, accessible, commercially viable, and cost-effective reality.

Boston Bioprocess helps biotech companies develop, scale up and optimize fermentation and DSP processes. We aim to remove knowledge and capacity bottlenecks in the transition from lab to commercial manufacturing.

Bravida is redefining what's possible in wound care and infection prevention, with a portfolio of transformative products and technologies that are clinically proven to deliver uncompromising freedom and protection

Cardio Diagnostics is a biotechnology company that makes cardiovascular disease prevention and early detection more accessible, personalized, and precise. The Company was formed to further develop and commercialize a proprietary Artificial Intelligence (AI)-driven Integrated Genetic-Epigenetic EngineTM ("Core Technology") for cardiovascular disease to become one of the leading medical technology companies for enabling improved prevention, early detection, and assists in the treatment of cardiovascular disease.

CellTrans is pioneering cell therapies for clinical application.

CiRC is a privately held, cell therapy company, developing treatments for serious diseases with high, unmet needs with an initial focus on the eye. Founded in 2019, CiRC is in pre-clinical development for the use of chemically induced retinal cells for vision restoration and specifically pursuing a treatment for Geographic Atrophy Age-Related Macular Degeneration (“Dry AMD”) and advanced Retinitis Pigmentosa (RP).

ClostraBiois dedicated to understanding and treating food allergies and other diseases of the immune system. The company is discovering and developing new therapeutics that modulate the protective ability of the microbiome.

Cosmos Health Inc. is a global healthcare group that was incorporated in 2009 in Chicago, Illinois. Cosmos Health Inc. is engaged in the nutraceuticals sector through its own proprietary lines of products "Sky Premium Life" and "Mediterranation." Additionally, the Company is operating in the pharmaceutical sector through the provision of a broad line of branded generics and OTC medications and is involved in the healthcare distribution sector through its subsidiaries in Greece and UK serving retail pharmacies and wholesale distributors. Cosmos Health is strategically focused on the R&D of novel patented nutraceuticals (IP) and specialized root extracts as well as on the R&D of proprietary complex generics and innovative OTC products. Cosmos has developed a global distribution platform and is currently expanding throughout Europe, Asia, and North America. Cosmos Health has offices and distribution centers in Thessaloniki and Athens, Greece and Harlow, UK. More information is available at www.cosmoshealthinc.com and www.skypremiumlife.com.

We are a group of dedicated scientific, medical, and business professionals who are driven to find treatments and cures to a variety of diseases. By attacking the disease directly with our novel nanoparticle-based technologies and working strategically with our medical and scientific partners we seek to provide treatments and cures previously unavailable to doctors and their patients.

Dimension Inx is the architect of regenerative microenvironments. Our materials give the body a blueprint to heal itself. We take a materials-centric approach to solving patient needs. By creating structures that emulate the body's microenvironment, we elicit an immediate regenerative response. We design for biofunctionality and manufacturability. Our platform is highly adaptable and not limited to any single material. Our collaborative studio approach allows us to co-create a lasting advantage by partnering with leading product and R&D organizations. Contact us to accelerate the development of new regenerative solutions today.

Dystrogen Therapeutics is a clinical stage chimeric cell therapy company focusing on rare diseases. The company is currently testing DEC therapy for Duchenne Muscular Dystrophy.

Elorac, Inc. is a specialty pharmaceutical company devoted to developing, commercializing, and marketing dermatology products. Elorac has over 20 novel prescription products in development. Our products embody proprietary technologies or compounds, all protected by patents or covered by proprietary technology.

Emalex Biosciences, LLC is a biopharmaceutical company dedicated to the development of new treatments for rare and orphan neurological conditions. Ecopipam, its first development candidate, is a novel compound that has been studied as a potential treatment for many central nervous system (CNS) disorders, including pediatric Tourette Syndrome. The latter is a childhood-onset neurodevelopmental condition characterized by motor and vocal tics for which very few safe and effective therapies exist.

Eton Pharmaceuticals, Inc. is a Deer Park, Illinois-based pharmaceutical company focused on developing and commercializing innovative pharmaceutical products utilizing the U.S. Food and Drug Administration’s 505(b)(2) regulatory pathway. Our mission is to advance healthcare through the introduction of innovative medicines that are affordable and available to all patients.

Evozyne designs novel protein therapeutics to solve previously unaddressable patient needs.

Grove Biopharma is a preclinical biotechnology startup, pioneering the discovery and development of a new class of synthetic biologic drug modality to access challenging drug targets. Our Precision-Linked Proteomimetic therapeutic platform has the potential to address significant unmet medical needs in oncology, neurodegenerative disease, and other rare diseases.

Inomagen Therapeutics is a private, preclinical-stage biotechnology company developing a non-viral gene therapy that targets the underlying mechanisms of atrial fibrillation.

Jaguar Gene Therapy, LLC is dedicated to accelerating breakthroughs in gene therapy for patients suffering from severe genetic diseases including those that impact sizeable patient populations. The company is made up of a proven team of experts with unparalleled CMC (Chemistry, Manufacturing and Controls), regulatory, clinical and commercial acumen who have first-hand experience in bringing novel gene therapy treatments to patients and their families. Committed to patient safety and product purity, Jaguar is rapidly advancing an initial pipeline of three programs targeting: 1) Type 1 galactosemia; 2) a genetic cause of autism spectrum disorder and Phelan-McDermid syndrome and other severe neurodevelopmental disorders with a SHANK3 mutation or deletion; and 3) Type 1 diabetes. The company continues to evaluate opportunities to expand its pipeline using the strength of the team and close relationships with numerous academic institutions.

MAIA Biotechnology is a targeted therapy, immune-oncology company, focused on development and commercialization of first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. A publicly traded company based in Chicago, MAIA (NYSE American: MAIA) is led by a passionate, principled and highly experienced Management Team with significant drug development experience, committed to advancing promising agents into human clinical trials. MAIA’s business strategy is designed to advance a strong value proposition for its portfolio of potentially novel compounds. MAIA controls risk and enhances its opportunity for success by diversifying and generating this portfolio of assets with a variety of compounds with novel mechanisms of action which have potential activity in multiple tumor types. MAIA’s business model involves placing drug candidates in their own dedicated, R&D focused subsidiary company, which is supported by the common infrastructure, management team, and resources of the MAIA enterprise. This model allows MAIA to provide more focused R&D support to each drug candidate, while also distributing shared central resources among subsidiary companies to maintain a lean, capital-efficient operating structure.

Maponos Therapeutics is a cellular therapy company dedicated to development of revolutionary therapeutics for different human diseases, including tissue fibrosis and cancers. We are focused on the cutting-edge technology and discovery of multiple types of cells for innovative and curative treatments. The company was recently cofounded by three faculty members who are affiliated with the University of Chicago School of Medicine and are among leaders in their respective fields. The company licensed the technologies and know-hows from the University of Chicago. The mission of Maponos Therapeutics is to address the unmet medical need by creating innovative treatment with next-generation cell therapeutics.

Maroon Biotech is a biotechnology company that specializes in surfactant chaperones to restore cell structure and viability disrupted by trauma.

Leading North American Specialty Pharmaceutical Company focused on hematology, rheumatology, auto-immune disease, specialty oncology and pediatrics.

Monopar Therapeutics is a clinical­-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. Monopar's pipeline consists of camsirubicin (Phase 1b) for the treatment of advanced soft tissue sarcoma; MNPR­101, a late-­stage preclinical antibody for radiopharmaceutical use in advanced cancers; and MNPR­202, an early-stage camsirubicin analog for various cancers.

Nephraegis Therapeutics is a biopharmaceutical company developing NPH-022 to prevent and treat Acute Kidney Injury (AKI).

OWP Pharmaceuticals provides FDA approved epilepsy medications to patients at affordable prices in the United States. We have created a business model that has a significant tie to a "Not for Profit" organization named the ROW Foundation. Through this model both organizations have a vision to drastically improve the lives of epilepsy patients throughout the world including under-resourced patients outside of the United States through increase education, diagnosis and treatment.

Oxalo Therapeutics is a committed to developing first-in-class therapeutics to treat and prevent diseases caused by hyperoxaluria and hyperoxalemia.

Pagari Life Science Corp is a biotechnology company dedicated to the development and commercialization of a new generation of safe anti-herpetic viral drugs and advanced healing drugs. The company is revolutionizing cold sore treatment with the commercial launch of Helocaine®.

The future of mental wellness is being built today. Through its diversified investment fund, Palo Santo is positioned to increase the supply of clinically effective, affordable, and accessible mental health and addiction treatment solutions needed in today's world. Supported by a rapidly growing body of evidence and strong FDA support, psychedelic-assisted treatments represent a paradigm shift in mental health care. Yet the emerging ecosystem of business opportunities is highly fragmented and, with a lack of institutional capital available, Palo Santo is targeting high growth opportunities within biotech & drug development, health care services, and digital health solutions led by passionate, experienced, and ethical management teams. These businesses are positioned to have a profound impact on treating conditions such as depression, PTSD, anxiety, OCD, drug and alcohol dependence, chronic pain, Alzheimer's, and a range of inflammatory-related illnesses.

Pathos was borne from the belief that cancer is a collection of hundreds of rare diseases and can be best described by pathways accounting for the pathophysiology of patients. We license or co-develop clinical-stage therapeutics to ensure highly efficacious drugs are developed for the patients most likely to benefit and with significant unmet needs. Our patient selection strategies are optimized for the fastest path to approval to improve patient outcomes as quickly as possible. Our aim is ultimately to accelerate the translation of real-world data into breakthrough therapies for patients that need them most.

Generics

Pharmazz, Inc. is an innovative biopharmaceutical company with an approved product, promising drug pipeline and a seasoned management team. It is a Delaware Corporation based in Willowbrook, Illinois, USA focused on discovering, acquiring, developing, and commercializing therapeutics that target critical care medicine. Pharmazz India Private Limited a majority owned subsidiary of Pharmazz, Inc. obtained marketing authorization of Lyfaquin® (INN: Centhaquine) in India. Pharmazz has licensed exclusive worldwide rights to several molecules indicated for critically ill patients from Midwestern University, Downers Grove, USA. The company has a strong patent position and robust pipeline in different stages of clinical development.

Phathom Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal (GI) diseases and disorders. The company is advancing the investigational agent vonoprazan, a novel potassium-competitive acid blocker (P-CAB). Vonoprazan has the potential to address multiple unmet needs among patients with gastroesophageal reflux disease (GERD) and other acid-related disorders. We have created a nimble, entrepreneurial environment that fosters the spirit of collective ownership, accountability, proprietorship and achievement — elements that are key to our success.

Prenosis, decision support tools use artificial intelligence to rapidly synthesize proprietary biological data and historical clinical data to predict future outcomes

SELAGINE, Inc. develops novel antibody-based biologic eye drops for treatment of immunological or inflammatory ocular surface diseases such as Dry Eye Disease, Sjögren’s syndrome and ocular Graft-versus-Host Disease.

Seurat Therapeutics is focused on developing medication to safely and effectively treat and prevent migraines.

SIWA Therapeutics is a privately held preclinical stage biotechnology company that has a monoclonal antibody that targets and destroys senescent cells. Our current therapeutic focus is on certain rare and fast track diseases, including cancer metastasis and muscle wasting diseases, such as muscular dystrophy. Beyond these indications, senescent cells are causally implicated in a wide variety of diseases including: neurodegenerative diseases; autoimmune conditions, and infectious diseases. SIWA is currently optimizing its lead antibody, SIWA 318, and in parallel, seeking partnerships to advance SIWA 318 and other related technologies to broaden and accelerate its development pipeline.

SkinCure Oncology is the only company offering GentleCure™—the most comprehensive approach to delivering advanced, nonsurgical treatment for basal cell carcinoma, squamous cell carcinoma, and other skin cancers using Image-Guided SRT. The company partners with quality-focused dermatologists and Mohs surgeons to bring cancer center-level radiation therapy to physician offices. From clinical, administrative, and operational backing to robust patient support, SkinCure Oncology ensures that practices are fully equipped to offer treatment with Image-Guided SRT. This advanced technology delivers calibrated doses of X-ray energy via the Sensus SRT-100 Vision™, the first and only skin cancer treatment platform with high-frequency ultrasound imaging. Adaptive radiotherapy protocols destroy malignant cancer cells while preserving healthy tissue surrounding the treated areas for optimal clinical and cosmetic outcomes and the ideal patient experience.

SparX Biopharmaceutical Corp. is a research-based development-stage biopharmaceutical company, dedicated to the mission of “strengthening human immunity using robust antibody therapies” through the discovery and development of innovative immuno-oncology agents. Equipped with big data analytical techniques, such as machine learning algorithms, SparX extracts potential interactions from large volumes of complex multi-dimensional public information. Mechanistic pharmacological analyses coupled with in vitro and in vivo evaluations using the syngeneic, transgenic and humanized mouse models, enables SparX’s focus on developing novel or best-in-class therapeutics demonstrating substantial advantages over existing therapies. Target discovery and validation has historically been the bottleneck in drug development. SparX combines its sophisticated target discovery platform with an integrated multi-component SAILING™ antibody optimization system and a cutting-edge bi-ADC technology to markedly improve the success rate of empowered antibody drug development. In addition to the integrated antibody discovery platform, SparX has built in-house cGMP facilities of significant capacity to produce clinical and commercial drug products, facilitating its evolution into an integrated and independent biopharmaceutical company.

Syenex is a synbio technology company that provides genetic medicine developers with access to best-in-class targeted delivery technologies (ex vivo & in vivo). Our goal is to accelerate clinical impact for developers of curative cell and gene therapies

SimBioSys is a pioneering TechBio company leveraging artificial intelligence and biophysical modeling to harness the power of spatial biophysics to redefine precision medicine, transform patient care and defeat cancer. By seeing cancer more completely, SimBioSys aims to empower clinicians and researchers with a more informed understanding of a patient’s tumor to optimally assess all available options and deliver on the promise of truly individualized patient care. To learn more, visit us at https://www.simbiosys.com/.

Syntax Bio is a preclinical-stage biotech company, overcoming longstanding challenges in stem cell-derived therapies by directly controlling and accelerating cell differentiation.

Tempus is making precision medicine a reality by applying AI in healthcare, deriving insights from our expansive library of clinical data and molecular data. We enable physicians to make real-time, data-driven decisions to deliver personalized care and targeted therapies for patients through our analytical machine learning platform that uses the power of artificial intelligence in healthcare. We also work with partners to facilitate discovery, development, and delivery of optimized therapeutic options for patients through distinctive solution sets. Our mission is for each patient to benefit from the treatment of others who came before by providing the healthcare industry tools that learn as we gather more data. It's About Time. For more information, visit tempus.com and follow us on Twitter (@TempusLabs).

TRACT Therapeutics, Inc. has developed a novel approach for restoring immune balance in patients receiving a solid organ transplant or in patients suffering from an autoimmune disease. This therapeutic approach may potentially reduce the chance of organ rejection following a transplant or transfer a patient suffering from an autoimmune disease into a state of remission. The proprietary technology is based on a platform which can be utilized to treat solid organ transplant patients, as well as a number of autoimmune disorders such as Crohn’s Disease. For organ transplant, it shows great promise in preventing rejection of a donated organ, thereby, reducing the need for a second transplant. Over the next few years, TRACT’s TregCel™ personalized therapy could transform the medical approach in transplant medicine by dramatically reducing or eliminating the lifelong use of toxic anti-rejection drugs.

Vanqua Bio is helping usher in a new era of hope for the millions of people living with neurodegenerative diseases. Our unique drug-development approach is designed to overcome longstanding challenges in the neuroscience field by capitalizing on the power of human genetics to identify genes that cause or increase the risk of neurodegenerative disease. We leverage novel, proprietary research tools and in vitro modeling of disease, based on patient-derived neuronal cells, to develop transformative therapies that slow or stop the progression of Parkinson’s disease (PD), Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and Gaucher disease (GD).

VIVACELLE BIO, Inc. is a developmental stage biotechnology company developing products utilizing nanoparticle technology. Their first product, VBI-1, a colloid non-blood volume expander appears to be safer and far more effective than the standard treatment for hypovolemia in animal studies and received green light from FDA to start a phase IIa clinical trial in hypovolemia due to blood loss. The immediate other product in the pipeline is VBI-S, targeting hypovolemia due to sepsis/septic shock. Hypovolemia results from inadequate fluid volume in the blood vessels, causes the death of over a one million people globally each year. Major causes for fluid loss are trauma, surgery, shock, sepsis, severe diarrhea and burns. Inadequate circulating volume impairs tissue perfusion and oxygenation leading to cell injury and death. Rapid volume replacement and re-establishment of normal blood pressure are essential for survival. Currently available options of fluid replacements are non-blood volume expanders (colloids and crystalloids), blood products and blood substitutes. They have proven to be impractical and have the potential for significant negative adverse effects. VBI-1, represents a new paradigm in fluid resuscitation, safely restoring blood vessel volume and reversing the effects of hypovolemia. VBI-1 also modulates Nitric Oxide (a potent vasodilator that drops the blood pressure and a precursor to highly highly toxic mediators), reduces reperfusion injury, inhibits the inflammatory response, clears the endotoxin, metabolizes to naturally-occurring components and acts as an energy source. In addition, it can be loaded with readily available oxygen.

Xentria is a venture studio that provides capital and insight into breakthrough science that aligns with our core therapeutic areas to improve the lives of patients and their families. Since our formation in 2020, we've forged authentic partnerships to advance challenging drug development, addressing unmet needs with increased collaboration, tenacity, and partnership. We offer holistic support, enhanced operational efficiency, and long-term partnerships to drive growth and assist in navigating challenges for an increased chance of success.

Xeris is a specialty pharmaceutical company leveraging novel formulation technology platforms to develop and commercialize ready-to-use, liquid-stable injectables.